Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nano-luteolin refers to a class of nanotechnology-based formulations in which the natural flavonoid luteolin is encapsulated or incorporated into nanoscale carriers such as polymeric nanoparticles, nanovesicles, micelles, or other delivery systems. These nanoformulations are designed to overcome the poor water solubility, low bioavailability, and rapid metabolism of free luteolin. By using nanocarriers (e.g., polymers like PEG or phospholipids), nano-luteolin enhances the solubility and stability of luteolin in biological environments and enables targeted delivery to tissues. Mechanistically, these formulations retain the pharmacological activities of luteolin—including anti-inflammatory, antioxidant, anticancer (notably against lung cancer), antibacterial (including activity against bacterial prostatitis), neuroprotective effects—by modulating multiple molecular pathways such as inhibition of PI3K/Akt-mediated NF-κB and MAPK signaling pathways. Nanoformulations have demonstrated improved therapeutic efficacy with reduced cytotoxicity compared to free luteolin in preclinical models[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nano-luteolin.